CPH:NOVO-B

Novo Nordisk A/S Earning Date

DENMARK |CO |DKK

NOVO-B Earnings Date

|
Report Date Period Ending Last Quarter's EPS Last Year's EPS
Oct 30, 2021 (est) Sep 30, 2021 kr5.26 kr4.41
Report Date Period Ending Last Quarter’s Revenue Last Year’s Revenue
Oct 30, 2021 (est) Sep 30, 2021 kr33.04B kr30.93B

Novo Nordisk A/S's next estimated earnings date (based on same quarter last year's date) is Oct 30, 2021 for the fiscal quarter ending Sep 30, 2021.

NOVO-B Earnings Date & History Chart

NOVO-B Earnings Date & Revenue History

NOVO-B Earnings History

|
Show More
Show More

NOVO-B Revenue History

|
Show More
Show More

Novo Nordisk A/S Next Earnings Date & Report

NOVO-B Aug 2021 (FQ) Earnings Date & Report Preview

NOVO-B's next estimated earnings date (based on same quarter last year's report date) is Oct 30, 2021 for the fiscal quarter ending Sep 30, 2021.

Novo Nordisk A/S Previous Earnings Dates & Reports

NOVO-B Previous Earnings Date & Report Recap: Jun 2021 (FQ)

Novo Nordisk A/S's previous earnings date was Aug 4, 2021 for its fiscal quarter ended Jun 30, 2021.

NOVO-B's earnings per share (EPS) was kr5.26, beating the consensus analysts forecast of kr4.77 by 10.27%.

The EPS was lower than the previous fiscal quarter (Mar 2021) by -3.51%, and higher than the same period a year before (Jun 2020) by 16.09%.

Revenues were $33.04B, down by -2.26% from the previous quarter , and up by 10.11% from the same period last year.

The company reported a net income of kr12.12B, -3.96% lower than the previous quarter, and higher by 14.10% than the same period a year before.

Free cash flow for the quarter was kr23.37B , compared to kr9.76B last quarter and kr22.89B a year before.

NOVO-B Previous Earnings Date & Report Recap: Dec 2020 (FY)

Novo Nordisk A/S's previous annual earnings date was Feb 3, 2021 for its fiscal year ended Dec 31, 2020.

NOVO-B's earnings per share (EPS) was kr18.00.

Revenues were kr126.95B, up by 4.04% from previous year's revenue.

The company reported a net income of kr42.14B, 8.18% higher than the previous year.

Novo Nordisk A/S reported a free cash flow of kr29.87B for its fiscal year, compared to kr35.55B a year ago.